The role of micafungin and anidulafungin in the treatment of systemic fungal infections: Applications and patents for two novel echinocandins

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 1, 2012, Pages 1-7

  Hinske, Ludwig Christian G ^a   Weis, Florian ^a   Heyn, Jens ^a   Hinske, Patricia ^b   Beiras Fernandez, Andres ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anidulafungin; Aspergillosis; Candidemia; Candidiasis; Echinocandins; Micafungin; Patent

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; RAPAMYCIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDEMIA; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; EOSINOPHILIA; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; HEMOLYTIC ANEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; INVASIVE CANDIDIASIS; LEUKOPENIA; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NONHUMAN; PATENT; PRIORITY JOURNAL; SIDE EFFECT; SKIN IRRITATION; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; PATENTS AS TOPIC;

EID: 84858306612     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112799829747     Document Type: Article

References (75)

1. Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: Rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Diagnost Microbiol Infect Dis 2001; 41(4): 211-4.
2. Morace G, Borghi E. Fungal infections in ICU patients: Epidemiology and the role of diagnostics. Minerva Anestesiol 2010; 76(11): 950-6.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39(3): 309-17.
4. Iwamoto, T., Fujie, A., Nitta, K., Tsurumi, Y., Shigematsu, N., Kasahara, C., Hino, M., Okuhara, M., Sakane, K., Kawabata, K., Ohki, H. Polypeptide compound and a process for preparation thereof. US5376634 (1994).
5. Burkhardt, F.J., Debono, M., Nissen, J.S., Turner, W.W. Cyclic peptide antifungal agents. US5965525 (1999).
6. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46(3): 485-7.
7. Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Medical mycology: Official publication of the International Society for Human and Animal. Mycology 2001; 39 (Suppl 1): 55-66.
8. Mazur P, Morin N, Baginsky W, el-Sherbeini M, Clemas JA, Nielsen JB, et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 1995; 15(10): 5671-81.
9. Beauvais A, Bruneau JM, Mol PC, Buitrago MJ, Legrand R, Latgé JP. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001; 183(7): 2273-9.
10. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002; 51(4): 247-55.
11. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362(9390): 1142-51.
12. Schwier, J.R., Taylor, J. Processes for making pharmaceutical oral ECB formulations and compositions. US006821951 (2004).
13. Alexander BD, Winkler TP, Shi S, Ashley ESD, Hickey AJ. Nebulizer delivery of micafungin aerosols. Pharmacotherapy 2011; 31(1): 52-7.
14. Shi S, Ashley ESD, Alexander BD, Hickey AJ. Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles. AAPS Pharm Sci Tech 2009; 10(1): 129-37.
15. Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, Chaturvedi V, et al. Reference method for broth dilution antifungal susceptibility testing of yeasts 3ed. Clinical and Laboratory Standards Institute 2008.
16. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14(4): 398-405.
17. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemotherap 2011.
18. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol 2011; 49(2): 624-9.
19. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Testing CSfAS. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemotherap 2010; 13(6): 180-95.
20. Perlin, D.S., Park, S., Douglas, C.M., Kahn, J.N., Parent, S.A., Kelly, R. Assays for resistance to echinocandin-class drugs. US20100075302 (2010).
21. Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemotherap 2008; 52(2): 539-50.
22. Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemotherap 2002; 46(6): 1857-69.
23. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida sp.: Microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemotherap 2002; 46(12): 3846-53.
24. Nguyen KT, Ta P, Hoang BT, Cheng S, Hao B, Nguyen MH, et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemotherap 2009; 53(8): 3347-52.
25. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother. 2004; 53(2): 386-9.
26. Vazquez JA, Sobel JD. Anidulafungin: A novel echinocandin. Clin Infect Dis. 2006; 43(2): 215-22.
27. Chandrasekar PH, Sobel JD. Micafungin: A new echinocandin. Clin Infect Dis. 2006; 42(8): 1171-8.
28. Hanadate T, Wakasugi M, Sogabe K, Kobayashi T, Horita H, Kawamura I, et al. Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report. J Infect Chemother 2011.
29. Thye D, Shepherd B, White RJ, Weston Ie, Henkel T. Anidulafungin: A Phase 1 Study to identify the maximum tolerated dose in healthy volunteers. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2001; 41: abstract no. A-36
30. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemotherap 2004; 48(6): 2021-4.
31. Chen SC-A, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: A comparison. Drugs 2011; 71(1): 11-41.
32. Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN, et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: A pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis. 2010; 29(2): 223-9.
33. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagnostic Microbiol Infect Dis 2008; 60(3): 329-31.
34. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005; 45(10): 1145-52.
35. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007; 3(1): 71-97.
36. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida sp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiolog 2008; 46(1):150-6.
37. Blyth CC, Chen SCA, Slavin MA, Serena C, Nguyen Q, Marriott D, et al. Not just little adults: Candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123(5): 1360-8.
38. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemotherap 2008; 52(1): 321-8.
39. Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007; 8(10): 1479-92.
40. Shimoeda S, Ohta S, Kobayashi H, Yamato S, Sasaki M, Kawano K. Effective blood concentration of micafungin for pulmonary aspergillosis. Biol Pharm Bull 2006; 29(9): 1886-91.
41. Spreghini E, Orlando F, Santinelli A, Pisa E, Loretelli C, Manso E, et al. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemotherap 2009; 53(9): 4035-9.
42. Olson JA, George A, Constable D, Smith P, Proffitt RT, Adler-Moore JP. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemotherap 2010; 54(9): 3884-94.
43. Clemons KV, Schwartz JA, Stevens DA. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Medical mycology: Official publication of the International Society for Human and Animal. Mycology 2011.
44. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan. J Infect 2010; 61(5): 410-8.
45. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/-mouse model of chronic granulomatous disease. Antimicrob Agents Chemotherap 2006; 50(2): 422-7.
46. Nagasaki Y, Eriguchi Y, Uchida Y, Miyake N, Maehara Y, Kadowaki M, et al. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. J Antimicrob Chemother 2009; 64(2): 379-82.
47. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Medical mycology: Official publication of the International Society for Human and Animal. Mycology 2006; 44(1): 69-73.
48. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004; 10(10): 925-8.
49. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemotherap 2000; 44(1): 57-62.
50. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: Review of the literature. Rev Iberoam Micol 2003; 20(4):121-36.
51. Selvakumar D, Miyamoto M, Furuichi Y, Komiyama T. Inhibition of beta-1,3-glucan synthase and cell growth of Cryptococcus species by recombinant single-chain anti-idiotypic antibodies. J Antibiot 2006; 59(2): 73-9.
52. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida sp., Cryptococcus neoformans and Aspergillus fumigatus: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagnost Microbiol Infect Dis 2011; 69(1): 45-50.
53. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: Comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemotherap 2011; 55(2): 561-6.
54. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. Echinocandin susceptibility testing of Candida isolates collected during a One-year Period in Sweden. J Clin Microbiol 2011.
55. Arendrup MC, Rodriguez-Tudela J-L, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M, et al. Echinocandin susceptibility testing of Candida sp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: Analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemotherap 2011; 55(4): 1580-7.
56. Park S, Kelly R, Kahn JN, Robles J, Hsu M-J, Register E, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrobial Agents Chemotherap 2005; 49(8):3264-73.
57. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemotherap 2006; 50(8): 2892-4.
58. Johnson ME, Katiyar SK, Edlind TD. A new Fks hotspot for acquired echinocandin resistance in yeast, and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemotherap 2011.
59. Perlin DS. Antifungal drug resistance: Do molecular methods provide a way forward? Curr Opin Infect Dis 2009; 22(6): 568-73.
60. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemotherap 2007; 10(3): 121-30.
61. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: Post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care (London, England) 2009; 13(5): R159.
62. Kuse E-R, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007; 369(9572): 1519-27.
63. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45(7): 883-93.
64. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39(6): 770-5.
65. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azolerefractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48(3): 304-9.
66. de Wet NTE, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21(7): 899-907.
67. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006; 53(5): 337-49.
68. van de Sande WWJ, Mathot RAA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJA, et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrobial Agents Chemotherap 2009; 53(5): 2005-13.
69. Takazono T, Izumikawa K, Mihara T, Kosai K, Saijo T, Imamura Y, et al. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrobial Agents Chemotherap 2009; 53(8): 3508-10.
70. Kaniga, K. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent. US007452861 (2011).
71. Hirata Y, Yokote T, Kobayashi K, Nakayama S, Oka S, Miyoshi T, et al. Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies. Leuk Lymphoma 2010; 51(5): 853-9.
72. van Burik J-AH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39(10): 1407-16.
73. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida sp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: Report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagnost Microbiol Infect Dis 2010; 68(3): 278-83.
74. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrobial Agents Chemotherap 2005; 49(8): 3317-24.
75. Kawada M, Fukuoka N, Kondo M, Okazaki K, Kusaka T, Kawada K, et al. Pharmacokinetics of prophylactic micafungin in very-lowbirth-weight infants. Pediatr Infect Dis J 2009; 28(9): 840-2.